Four biotechs hit Wall Street with upsized IPOs, each raising more than $20M over their goals
Four more biotechs have jumped onto Nasdaq, each raising over $20 million more than their initial goals and adding to this year’s record-high total raise of more than $14 billion.
Seer, Sigilon Therapeutics, Silverback Therapeutics, and Kinnate Biopharma raked in $175 million, $126 million, $241.5 million and $240 million respectively.
Seer priced its upsized offering of 9.2 million shares at $19 apiece, above a $16 to $18 range it set earlier this week. The Redwood City, CA-based biotech initially set out for a $150 million raise. It was launched by CEO Omid Farokhzad, who left his gig in a nano-medicine lab at Boston’s Brigham and Women’s Hospital about two years ago to build a company around technology he said would change the field of proteomics.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.